Anaphylaxis with Macugen

Pfizer Pharmaceuticals has alerted healthcare professionals that severe allergic reactions have occurred in patients treated with Macugen. Macugen (pegaptanib sodium injection) is used to slow vision loss in people with the neovascular or "wet" form of age-related macular degeneration.

In rare cases, anaphylaxis or anaphylactoid reactions, including angioedema, have been reported after patients received Macugen along with other medications used to prepare for the injection. A direct relationship hasn't been established between these reactions and Macugen or any of the other drugs. However, the company says that the patient's history should be evaluated for hypersensitivity reactions before giving the treatment.

Category:

News & Politics

Tags:

• Macugen
• Anaphylaxis
• FDA
• Drug
• Reaction
• Macular
• Degeneration
• Patient
• Safety